Glucocorticoids & adipocyte function in human obesity

糖皮质激素

• 批准号: 8054199
• 负责人: Susan K Fried
• 金额: $ 35.94万
• 依托单位: BOSTON MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8054199
• 关键词: Abdomen; Address; Adipocytes; Adipose tissue; Affect; American; Apoptosis; Bioinformatics; Candidate Disease Gene; Cardiovascular Diseases; Central obesity; Chronic; Cluster Analysis; Comorbidity; Complex; Cortisone; Cushing Syndrome; Data; Deposition; Diabetes Mellitus; Endocrine; Epidemic; Experimental Designs; Fasting; Fatty acid glycerol esters; Gene Expression; Gene Targeting; Generations; Genes; Glucocorticoids; Goals; Health; Hormones; Human; Hydrocortisone; Hydroxysteroid Dehydrogenases; Immune; In Vitro; Inflammation; Ingestion; Insulin; Leptin; Leucine Zippers; Lipolysis; Literature; Mediating; Metabolic; Metabolism; Molecular; Non-Insulin-Dependent Diabetes Mellitus; Nutritional; Obesity; Omentum; Operative Surgical Procedures; Organ Culture Techniques; Overweight; Pathway interactions; Peripheral; Phenotype; Physiologic pulse; Physiology; Production; Quality of life; Regulation; Research; Risk; Role; Sampling; Serum; Small Interfering RNA; Stress; Testing; Therapeutic Intervention; Time; Variant; Visceral; Work; adipokines; base; cell type; feeding; high risk; immune function; in vivo; insight; novel; obesity risk; overexpression; prevent; research study; response; subcutaneous

DESCRIPTION (provided by applicant): Obesity, particularly visceral and upper body subcutaneous obesity, is associated with higher risk for obesity-related co-morbidities, including type 2 diabetes and cardiovascular disease. Glucocorticoids (GC) are powerful regulators of fat deposition and fat distribution. Obesity is associated with an increase in local cortisol production within both subcutaneous and visceral adipose tissues. In addition, visceral (omental) adipose tissue is more responsive to GC in vitro, suggesting depot differences in GC action contribute to depot differences in fat cell metabolism and endocrine function. Our preliminary gene array studies show that chronic treatment of human adipose tissue with GCs regulates numerous genes related to metabolism and inflammation in vitro, and identified several potentially important GC targets that could contribute to the depot-specific activation of different gene networks. The relevance of these changes to in vivo physiology and the underlying mechanisms by which GC coordinate the activity of different gene networks that regulate the metabolic and endocrine functions of the adipocyte remain unclear. Thus, Specific Aim 1 of the current proposal will focus on identifying the genes in abdominal subcutaneous adipose tissue that are regulated by glucocorticoids in vivo. Because GC effects depend on nutritional state/insulin, we will compare the effects of hydrocortisone administered in the fasted state or in combination with meals, on global gene expression (Affymatrix gene arrays). Adipose tissue will be sampled 3.5h after hydrocortisone administration (with or without a meal) to determine primary GC target genes. To elucidate the mechanisms underlying the differential effects of GC in visceral fat, Specific Aim 2 will compare GC-regulated gene expression in organ cultures of Abd sc and omental adipose tissue and primary adipocytes in vitro using a candidate gene approach. Specific Aim 3 will test the functional importance of apparent primary GC targets at the level of the adipocyte with analysis of alterations in the expression of downstream targets using analysis of candidate genes and gene arrays, and functional changes in adipocyte metabolism and adipokine secretion. Collectively, these data will enhance understanding of the mechanisms by which GC promote obesity, particularly visceral fat deposition, by pointing to novel targets for therapeutic intervention for visceral obesity and its metabolic complications. PUBLIC HEALTH RELEVANCE: The `diabesity' epidemic and its metabolic complications detract from the quality of life of the majority of Americans. Our proposed work addresses the mechanisms by which glucocorticoids, hormones secreted during stress, regulate the amount of fat deposited in human adipose tissues, and whether the fat is mainly deposited in central (abdominal) or peripheral depots and hence contribute to risk for developing diabetes and cardiovascular disease. These data will provide a critical first step to unraveling the complex, pleiotropic effects of GC in human adipose tissues. Furthermore, identifying the key targets of GC action in fat may provide novel insights into the effects of GC in orchestrating the integration of the endocrine, immune and metabolic functions of the adipocyte.

描述（由申请人提供）：肥胖，特别是内脏和上身皮下肥胖，与肥胖相关合并症（包括2型糖尿病和心血管疾病）的风险较高相关。糖皮质激素（GC）是脂肪沉积和脂肪分布的强有力的调节剂。肥胖与皮下和内脏脂肪组织内局部皮质醇产生的增加有关。此外，内脏（网膜）脂肪组织在体外对GC反应更敏感，表明GC作用的储库差异有助于脂肪细胞代谢和内分泌功能的储库差异。我们的初步基因阵列研究表明，长期治疗人类脂肪组织与GC调节许多基因相关的代谢和炎症在体外，并确定了几个潜在的重要GC目标，可能有助于特定的仓库激活不同的基因网络。这些变化与体内生理学的相关性以及GC协调调节脂肪细胞代谢和内分泌功能的不同基因网络活性的潜在机制仍不清楚。因此，本提案的具体目标1将集中于鉴定腹部皮下脂肪组织中受体内糖皮质激素调节的基因。由于GC效应取决于营养状态/胰岛素，我们将比较在禁食状态下或与膳食组合施用的氢化可的松对整体基因表达的影响（Affymatrix基因阵列）。在氢化可的松给药后3.5小时（伴或不伴进餐）对脂肪组织进行采样，以确定主要GC靶基因。为了阐明GC在内脏脂肪中差异效应的潜在机制，特定目标2将使用候选基因方法在体外比较Abd sc和网膜脂肪组织和原代脂肪细胞器官培养物中GC调节的基因表达。具体目标3将在脂肪细胞水平上检测表观主要GC靶标的功能重要性，并使用候选基因和基因阵列分析下游靶标表达的变化，以及脂肪细胞代谢和脂肪因子分泌的功能变化。总的来说，这些数据将通过指向内脏肥胖及其代谢并发症的治疗干预的新靶点，增强对GC促进肥胖，特别是内脏脂肪沉积的机制的理解。 公共卫生相关性：“糖尿病”流行病及其代谢并发症降低了大多数美国人的生活质量。我们提出的工作解决的机制，糖皮质激素，在压力下分泌的激素，调节沉积在人体脂肪组织中的脂肪量，以及脂肪是否主要沉积在中央（腹部）或外周仓库，因此有助于发展糖尿病和心血管疾病的风险。这些数据将为阐明GC在人体脂肪组织中复杂的多效性作用提供关键的第一步。此外，确定脂肪中GC作用的关键靶点可能会为GC在协调脂肪细胞内分泌，免疫和代谢功能整合中的作用提供新的见解。